Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer - PubMed (original) (raw)
Comparative Study
. 1998 Jan-Feb;2(1):67-71.
doi: 10.1016/s1091-255x(98)80105-4.
M Shashidharan, A G Thorson, C A Ternent, G J Blatchford, M A Christensen, P Watson, S J Lemon, B Franklin, B Karr, J Lynch, H T Lynch
Affiliations
- PMID: 9841970
- DOI: 10.1016/s1091-255x(98)80105-4
Comparative Study
Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer
K M Lin et al. J Gastrointest Surg. 1998 Jan-Feb.
Abstract
The extracolonic tumor spectrum of hereditary nonpolyposis colorectal cancer (HNPCC) includes cancer of the endometrium, ovaries, stomach, biliary tract, and urinary tract. This study was designed to determine the penetrance of colorectal and extracolonic tumors in HNPCC mutation carriers. Forty-nine patients (22 females and 27 males) were identified with an MSH2 germline mutation, and 56 patients (28 females and 28 males) were identified with an MLH1 I mutation. Cumulative incidence by age 60 (lifetime risk) and mean age of cancer diagnosis were compared. The lifetime risk of extracolonic cancers in MSH2 and MLH1 carriers was 48% and 11%, respectively (P = 0.016). Extracolonic cancer risk in MSH2 females and males was 69% and 34%, respectively (P = 0.042). Mean age of extracolonic cancer diagnosis was significantly older for MSH2 males than females (55.4 vs. 39.0, P = 0.013). No difference was observed in colorectal cancer risk between MLH1 and MSH2 carriers (84% vs. 71%). Colorectal cancer risk was 96% in MSH2 males compared to 39% in MSH2 females (P = 0.034). No differences in colorectal and extracolonic cancer risks between MLH1 females and males were identified. The risk of extracolonic cancer by age 60 was greater in MSH2 mutation carriers than in MLH1 carriers. Gender differences in colorectal and extracolonic cancer risk were observed for MSH2 carriers only. These phenotypic features of HNPCC genotypes may have clinical significance in the design of genotype-specific screening, surveillance, and follow-up for affected individuals.
Similar articles
- Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population.
Lin KM, Shashidharan M, Ternent CA, Thorson AG, Blatchford GJ, Christensen MA, Lanspa SJ, Lemon SJ, Watson P, Lynch HT. Lin KM, et al. Dis Colon Rectum. 1998 Apr;41(4):428-33. doi: 10.1007/BF02235755. Dis Colon Rectum. 1998. PMID: 9559626 - MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT. Vasen HF, et al. J Clin Oncol. 2001 Oct 15;19(20):4074-80. doi: 10.1200/JCO.2001.19.20.4074. J Clin Oncol. 2001. PMID: 11600610 - Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene.
Lage PA, Albuquerque C, Sousa RG, Cravo ML, Salazar M, Francisco I, Maia L, Claro I, Suspiro A, Rodrigues P, Raposo H, Fidalgo PA, Nobre-Leitão C. Lage PA, et al. Cancer. 2004 Jul 1;101(1):172-7. doi: 10.1002/cncr.20320. Cancer. 2004. PMID: 15222003 - Mutations predisposing to hereditary nonpolyposis colorectal cancer.
Peltomäki P, de la Chapelle A. Peltomäki P, et al. Adv Cancer Res. 1997;71:93-119. doi: 10.1016/s0065-230x(08)60097-4. Adv Cancer Res. 1997. PMID: 9111864 Review. - Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database.
Peltomäki P, Vasen H. Peltomäki P, et al. Dis Markers. 2004;20(4-5):269-76. doi: 10.1155/2004/305058. Dis Markers. 2004. PMID: 15528792 Free PMC article. Review.
Cited by
- [Gender-specific differences in the development of colorectal cancer in Lynch syndrome patients-A systematic review].
Dohmen J, Sommer N, van Beekum K, Nattermann J, Engel C, Kalff JC, Hüneburg R, Vilz TO. Dohmen J, et al. Chirurgie (Heidelb). 2024 Sep;95(9):696-708. doi: 10.1007/s00104-024-02159-x. Epub 2024 Aug 15. Chirurgie (Heidelb). 2024. PMID: 39145869 Review. German. - Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer.
Capasso I, Santoro A, Lucci Cordisco E, Perrone E, Tronconi F, Catena U, Zannoni GF, Scambia G, Fanfani F, Lorusso D, Duranti S. Capasso I, et al. Cancers (Basel). 2023 Feb 22;15(5):1400. doi: 10.3390/cancers15051400. Cancers (Basel). 2023. PMID: 36900193 Free PMC article. Review. - Potential risks associated with the use of ionizing radiation for imaging and treatment of colorectal cancer in Lynch syndrome patients.
Sun M, Moquet J, Ellender M, Bouffler S, Badie C, Baldwin-Cleland R, Monahan K, Latchford A, Lloyd D, Clark S, Anyamene NA, Ainsbury E, Burling D. Sun M, et al. Fam Cancer. 2023 Jan;22(1):61-70. doi: 10.1007/s10689-022-00299-9. Epub 2022 Jun 20. Fam Cancer. 2023. PMID: 35718836 Free PMC article. Review. - Cumulative risks of colorectal cancer in Han Chinese patients with Lynch syndrome in Taiwan.
Kamiza AB, Wang WC, You JF, Tang R, Chien HT, Lai CH, Chiu LL, Lo TP, Hung KY, Hsiung CA, Yeh CC. Kamiza AB, et al. Sci Rep. 2021 Apr 26;11(1):8899. doi: 10.1038/s41598-021-88289-2. Sci Rep. 2021. PMID: 33903664 Free PMC article. Clinical Trial. - Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas.
Cho YA, Kim D, Lee B, Shim JH, Suh YL. Cho YA, et al. J Neurooncol. 2021 May;153(1):43-53. doi: 10.1007/s11060-021-03710-0. Epub 2021 Apr 17. J Neurooncol. 2021. PMID: 33864561
References
- Gastroenterology. 1997 Feb;112(2):594-642 - PubMed
- Cancer. 1996 Sep 15;78(6):1149-67 - PubMed
- Am J Gastroenterol. 1994 Apr;89(4):605-9 - PubMed
- Cancer Res. 1994 Sep 1;54(17):4590-4 - PubMed
- Int J Cancer. 1996 Feb 20;69(1):55-7 - PubMed